@Article{Świerzko2003,
journal="Central European Journal of\ Immunology",
issn="1426-3912",
volume="28",
number="2",
year="2003",
title="Review paperThe lectin pathway of complement activation. The role of complement in pathological processes and possible strategies of its activity modulation in therapy of some diseases",
abstract=" Abstract   Complement activation pathways with particular attention to lectin pathway were reminded. The current trend is that detailed knowledge of activation triggers and substrates  may pave the way to clinical interventions, i.e. inhibition of undesirable excessive activation of complement. Cellular receptors, possible inhibitors of complement cascade, and a list of diseases in which inhibition of complement is needed were shown. C1-inhibitor has its established value in the treatment of hereditary angioedema, but several other inhibitors, like soluble complement receptors, anti-C3 (-C3a), anti-C5 (-C5a) are proposed as therapeutic agents. These inhibitors may be useful in decreasing tissue lesions in such dangerous diseases as eg. Ischemic stroke, myocardial infarct, and septicemia (septic shock).Recently, also mannan binding lectins may be used in therapeutic interventions.",
author="Świerzko, Anna
and Madaliński, Kazimierz
and Cedzyński, Maciej",
pages="67--73",
url="https://www.termedia.pl/Review-paper-The-lectin-pathway-of-complement-activation-The-role-of-complement-in-pathological-processes-and-possible-strategies-of-its-activity-modulation-in-therapy-of-some-diseases,10,1647,1,1.html"
}